D. Hanahan and R. Weimberg, The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000.
DOI : 10.1016/S0092-8674(00)81683-9

I. Hay, J. Ryan, C. Grant, E. Bergstralh, J. Van-heerden et al., Prognostic significance of nondiploid DNA determined by flow cytometry in sporadic and familial medullary thyroid carcinoma, Surgery, vol.108, pp.979-980, 1990.

U. Bergholm, H. Adami, G. Auer, R. Bergström, M. Bäckdahl et al., Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden, Cancer, vol.9, issue.1, pp.135-142, 1989.
DOI : 10.1002/1097-0142(19890701)64:1<135::AID-CNCR2820640123>3.0.CO;2-G

E. Ekman, U. Bergholm, M. Bäckdahl, H. Adami, R. Bergström et al., Nuclear DNA content and survival in medullary thyroid carcinoma, Cancer, vol.9, issue.3, pp.511-517, 1990.
DOI : 10.1002/1097-0142(19900201)65:3<511::AID-CNCR2820650323>3.0.CO;2-B

Y. Ke, Z. Dou, J. Zhang, and X. Yao, Function and regulation of Aurora/Ipl1p kinase family in cell division, Cell Research, vol.110, issue.5170, pp.69-81, 2003.
DOI : 10.1073/pnas.152205299

M. Carmena and W. Earnshaw, The cellular geography of aurora kinases, Nature Reviews Molecular Cell Biology, vol.4, issue.11, pp.842-854, 2003.
DOI : 10.1038/nrm1245

J. Bischoff and G. Plowman, The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis, Trends in Cell Biology, vol.9, issue.11, pp.454-459, 1999.
DOI : 10.1016/S0962-8924(99)01658-X

S. Ulisse, Y. Arlot-bonnemains, E. Baldini, S. Morrone, S. Carocci et al., Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity, Journal of Endocrinology, vol.204, issue.2, pp.135-142, 2010.
DOI : 10.1677/JOE-09-0257
URL : https://hal.archives-ouvertes.fr/inserm-00435105

P. Trimboli, S. Ulisse, F. Graziano, A. Marzullo, M. Ruggieri et al., Trend in Thyroid Carcinoma Size, Age at Diagnosis, and Histology in a Retrospective Study of 500 Cases Diagnosed Over 20 Years, Thyroid, vol.16, issue.11, pp.1151-1155, 2006.
DOI : 10.1089/thy.2006.16.1151

J. De-groot, T. Links, J. Plukker, C. Lips, and R. Hofstra, as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors, Endocrine Reviews, vol.27, issue.5, pp.535-560, 2006.
DOI : 10.1210/er.2006-0017

M. Schlumberger, F. Carlomagno, E. Baudin, J. Bidart, and M. Santoro, New therapeutic approaches to treat medullary thyroid carcinoma, Nature Clinical Practice Endocrinology & Metabolism, vol.67, issue.1, pp.22-32, 2008.
DOI : 10.1038/ncpendmet0717

D. Ball, Medullary thyroid cancer: therapeutic targets and molecular markers, Current Opinion in Oncology, vol.19, issue.1, pp.18-23, 2007.
DOI : 10.1097/CCO.0b013e32801173ea

A. Kawasaki, I. Matsumura, M. Ji, S. Ezoe, H. Tanaka et al., Downregulation of an Aim-1 Kinase Couples with Megakaryocytic Polyploidization of Human Hematopoietic Cells, The Journal of Cell Biology, vol.17, issue.2, pp.275-287, 2001.
DOI : 10.1016/S0301-472X(99)00124-1

F. Gizatullin, Y. Yao, V. Kung, M. Harding, M. Loda et al., The Aurora Kinase Inhibitor VX-680 Induces Endoreduplication and Apoptosis Preferentially in Cells with Compromised p53-Dependent Postmitotic Checkpoint Function, Cancer Research, vol.66, issue.15, pp.7668-7677, 2006.
DOI : 10.1158/0008-5472.CAN-05-3353

K. Yoshimoto, H. Iwahana, A. Fukuda, T. Sano, S. Saito et al., Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism, Cancer Res, vol.52, pp.5061-5064, 1992.

M. Green, J. Woolery, and D. Mahadevan, Update on aurora kinase targeted therapeutics in oncology, Expert Opinion on Drug Discovery, vol.114, issue.18, pp.291-307, 2011.
DOI : 10.1073/pnas.1008366107